Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors. The company's mission is to harness the body's immune system to combat cancer through its proprietary Multi-Antigen Recognizing T cell (MAR-T) technology. This approach involves the selective expansion of non-genetically engineered, tumor-specific T cells capable of recognizing multiple tumor-associated antigens (TAAs), thereby enhancing the immune response against diverse cancer cells. By targeting multiple antigens simultaneously, MAR-T cells aim to reduce the likelihood of tumor escape mechanisms, offering a potentially more effective and safer alternative to existing therapies.
Marker's strategic focus centers on advancing its MAR-T cell platform to address unmet needs in oncology. The company is developing both autologous (patient-derived) and allogeneic (donor-derived) T cell therapies. Key objectives include:
- Autologous MAR-T Cell Products: Targeting hematological malignancies such as lymphoma and solid tumors like pancreatic cancer.
- Allogeneic MAR-T Cell Products: Developing off-the-shelf therapies for conditions including acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).
The company's approach leverages non-genetically engineered T cells, which are believed to be easier and less expensive to manufacture, with reduced toxicities compared to current engineered CAR-T and TCR-based therapies.
As of December 31, 2024, Marker Therapeutics reported cash and cash equivalents of approximately $19.2 million. The company has secured non-dilutive funding from various grant agencies, including the Cancer Prevention and Research Institute of Texas (CPRIT), the FDA's Orphan Products Grant program, and the National Institutes of Health Small Business Innovation Research (SBIR) program. These grants support the clinical investigation of Marker’s lead product candidates, such as MT-401 and MT-601.
Marker's pipeline includes several promising candidates:
- MT-601: An autologous MAR-T cell product targeting six tumor antigens, currently in a Phase 1 trial (APOLLO) for patients with lymphoma who have relapsed after anti-CD19 CAR-T cell therapy or are ineligible for such treatments. Early data indicate a favorable safety profile and objective responses in 78% of participants, with 44.4% achieving complete responses.
- MT-401: An allogeneic MAR-T cell product for post-transplant AML patients, which has received orphan drug designation from the FDA. Clinical trials have demonstrated a favorable safety profile and potential clinical benefit.
The company's MAR-T cell platform is distinguished by its ability to selectively expand tumor-specific T cells from a patient’s or donor’s blood, capable of recognizing a broad range of tumor antigens without genetic modification. This approach aims to enhance tumoricidal effects while minimizing the risk of tumor immune escape and reducing manufacturing complexity and costs.
Key members of Marker Therapeutics' leadership team include:
- Dr. Juan F. Vera: President and CEO, with extensive experience in cancer immunotherapy and a background in developing T cell-based therapies.
- Peter L. Hoang: Former President and CEO, who led the company through significant strategic initiatives.
In May 2023, Marker announced a comprehensive agreement with CellReady™, a newly formed Contract Development and Manufacturing Organization (CDMO). Under this agreement, CellReady purchased certain manufacturing assets from Marker and assumed related personnel and facility leases. This strategic move is designed to extend Marker’s financial runway and allow the company to focus on the clinical advancement of its T cell therapies.
The immuno-oncology sector is highly competitive, with several companies developing T cell-based therapies:
- Sellas Life Sciences: Focuses on cancer immunotherapies.
- ImmunoCellular Therapeutics: Develops immune-based therapies for various cancers.
- Celldex Therapeutics: Specializes in monoclonal and bispecific antibodies.
- Advaxis: Develops next-generation cancer immunotherapies.
In June 2025, Marker announced a collaboration with Cellipont Bioservices for the cGMP manufacturing of MT-601. This partnership aims to accelerate clinical supply and lay the foundation for potential pivotal trials and commercial readiness.
Marker's strategic considerations include focusing on the development of its MAR-T cell therapies, leveraging non-dilutive funding sources, and forming strategic partnerships to enhance manufacturing capabilities. The company's non-genetically engineered approach offers potential advantages in safety, manufacturing efficiency, and cost-effectiveness compared to engineered T cell therapies.
Looking ahead, Marker plans to advance its clinical programs, particularly MT-601 for lymphoma and MT-401 for AML, while exploring opportunities to expand its MAR-T cell platform into other hematological malignancies and solid tumors. The company aims to address significant unmet medical needs by providing innovative and effective immunotherapies.
For more information, visit Marker Therapeutics' official website:
Note: Specific contact details such as email addresses and physical addresses are not provided in this profile.
